
Evolus (EOLS) Stock Forecast & Price Target
Evolus (EOLS) Analyst Ratings
Bulls say
Evolus is supported by resilient demand in the cash-pay aesthetics market, with Q3 revenue of $78.0M, up 13% year over year and slightly ahead of consensus, while adjusted EBITDA turned positive for a fourth consecutive quarter at $1.2M. The company is also broadening its growth base beyond Jeuveau through Evolysse, which generated $7.9M and reached more than 4,500 customers, alongside strong retention metrics including a cumulative reorder rate above 70% and rewards membership above 1.6M. Management’s maintained FY26 revenue guidance of $330M-$337M, tightened opex outlook, and reaffirmed 2028 targets, combined with a visible pipeline of launches, support the view that Evolus can scale revenue and margin expansion over time.
Bears say
Evolus is facing a more cautious outlook because outyear revenue estimates were modestly reduced to reflect more conservative toxin market growth assumptions, signaling slower category expansion than previously expected. Although the revision has only a minimal impact on adjusted EBITDA estimates, it still points to limited near-term operating leverage and suggests that incremental sales growth may not translate meaningfully into stronger profitability. With Jeuveau and Evolysse dependent on sustained demand in the cash-pay aesthetic market across the United States, Canada, Europe, and Australia, a softer growth backdrop raises concerns about the company’s ability to accelerate fundamentals.
This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.
Evolus (EOLS) Analyst Forecast & Price Prediction
Start investing in Evolus (EOLS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Evolus (EOLS) Forecast
Evolus (EOLS) Analyst Forecast & Price Prediction
Start investing in Evolus (EOLS)
Order type
Buy in
Order amount
Est. shares
0 shares